Prior chemotherapy appears to limit the expansion and efficacy of chimeric antigen receptor T-cells in children with certain types of cancer, according to research reported in advance of the American Association for Cancer Research's annual meeting. Specific types of chemotherapeutic drugs, such as doxorubicin and cyclophosphamide, were associated with depleted T cell energy reserve, a sign of poor clinical performance, and efficacy appears to be influenced by the fuel pathways used by T cells. The findings could lead to alternate approaches "to make sure that we make a highly functional CAR T-cell product, not only for kids with leukemia but also for potentially solid-tumor CARs," said Dr. David Barrett of Children's Hospital of Philadelphia.
Researchers look for best cells for pediatric T-cell therapies
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.